Rachael Skyner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachael Skyner has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Frank von Delft
Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK
10 shared publications - Daren Fearon
Diamond Light Source
8 shared publications - Anthony Aimon
Diamond Light Source Ltd Harwell Science and Innovation Campus OX11 0QX Didcot UK
7 shared publications - Alice Douangamath
Diamond Light Source
6 shared publications - Louise Dunnett
Diamond Light Source Ltd., Harwell Science and Innovation Campus
6 shared publications - Tobias Krojer
MAX IV Laboratory Lund University Lund Sweden
6 shared publications
Latest Publications
- Open Access
A framework for testing structural hypotheses of protein dynamics against experimental HDX-MS data
Protein dynamics determine biological function, yet extracting structural ensembles from Hydrogen–Deuterium Exchange Mass Spectrometry (HDX-MS) remains a challenging inverse problem. Current ensemble-fitting approaches often achieve good agreement with uptake curves but lack rigorous validation and uncertainty quantification, limiting structural confidence. We propose ValDX, a validation framework for quantitative integration of HDX-MS data with structural ensembles. ValDX combines overlap-aware data splitting, replicate-based uncertainty estimation, and uptake-independent “Work Done” metrics that quantify how much an ensemble must be modified to match experiment. Across 22 ensembles spanning six proteins (58–474 residues), we show that conventional error metrics fail to distinguish structurally representative ensembles from incorrect ones, whereas Work Done metrics robustly discriminate global and local conformational quality. We further demonstrate that clustering yields compact, interpretable ensembles with minimal loss of accuracy, and that staged optimisation enables reliable fitting of both ensemble weights and forward-model parameters without requiring a reference structure. Together, this framework establishes HDX-MS ensemble integration as a quantitative structural hypothesis-testing problem, enabling inference of protein dynamics from HDX-MS data.
Open AccessA framework for testing structural hypotheses of protein dynamics against experimental HDX-MS data
Protein dynamics determine biological function, yet extracting structural ensembles from Hydrogen–Deuterium Exchange Mass Spectrometry (HDX-MS) remains a challenging inverse problem. Current ensemble-fitting approaches often achieve good agreement with uptake curves but lack rigorous validation and uncertainty quantification, limiting structural confidence. We propose ValDX, a validation framework for quantitative integration of HDX-MS data with structural ensembles. ValDX combines overlap-aware data splitting, replicate-based uncertainty estimation, and uptake-independent “Work Done” metrics that quantify how much an ensemble must be modified to match experiment. Across 22 ensembles spanning six proteins (58–474 residues), we show that conventional error metrics fail to distinguish structurally representative ensembles from incorrect ones, whereas Work Done metrics robustly discriminate global and local conformational quality. We further demonstrate that clustering yields compact, interpretable ensembles with minimal loss of accuracy, and that staged optimisation enables reliable fitting of both ensemble weights and forward-model parameters without requiring a reference structure. Together, this framework establishes HDX-MS ensemble integration as a quantitative structural hypothesis-testing problem, enabling inference of protein dynamics from HDX-MS data.
- Open Access
- 24 November 2024
- Published by Wiley in Applied Research
- Vol. 4 (1)
Accelerating Drug Discovery With High‐Throughput Crystallographic Fragment Screening and Structural Enablement
Fragment‐based drug discovery is a well‐established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low‐throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead‐like molecules.
- 24 November 2024
- Published by Wiley in Applied Research
- Vol. 4 (1)
Open AccessAccelerating Drug Discovery With High‐Throughput Crystallographic Fragment Screening and Structural Enablement
Fragment‐based drug discovery is a well‐established method for the identification of chemical starting points for development into clinical candidates. Historically, crystallographic fragment screening was perceived to be low‐throughput and time consuming. However, thanks to advances in synchrotron capabilities and the introduction of dedicated facilities, such as the XChem platform at Diamond Light Source, there have been substantial improvements in throughput and integration between sample preparation, data collection and hit identification. Herein we share our experiences of establishing a crystallographic fragment screening facility, our learnings from operating a user programme for ten years and our perspective on applying structural enablement to rapidly progress initial fragment hits to lead‐like molecules.
- Open Access
Learnt representations of proteins can be used for accurate prediction of small molecule binding sites on experimentally determined and predicted protein structures
Protein-ligand binding site prediction is a useful tool for understanding the functional behaviour and potential drug-target interactions of a novel protein of interest. However, most binding site prediction methods are tested by providing crystallised ligand-bound (holo) structures as input. This testing regime is insufficient to understand the performance on novel protein targets where experimental structures are not available. An alternative option is to provide computationally predicted protein structures, but this is not commonly tested. However, due to the training data used, computationally-predicted protein structures tend to be extremely accurate, and are often biased toward a holo conformation. In this study we describe and benchmark IF-SitePred, a protein-ligand binding site prediction method which is based on the labelling of ESM-IF1 protein language model embeddings combined with point cloud annotation and clustering. We show that not only is IF-SitePred competitive with state-of-the-art methods when predicting binding sites on experimental structures, but it performs better on proxies for novel proteins where low accuracy has been simulated by molecular dynamics. Finally, IF-SitePred outperforms other methods if ensembles of predicted protein structures are generated.
Open AccessLearnt representations of proteins can be used for accurate prediction of small molecule binding sites on experimentally determined and predicted protein structures
Protein-ligand binding site prediction is a useful tool for understanding the functional behaviour and potential drug-target interactions of a novel protein of interest. However, most binding site prediction methods are tested by providing crystallised ligand-bound (holo) structures as input. This testing regime is insufficient to understand the performance on novel protein targets where experimental structures are not available. An alternative option is to provide computationally predicted protein structures, but this is not commonly tested. However, due to the training data used, computationally-predicted protein structures tend to be extremely accurate, and are often biased toward a holo conformation. In this study we describe and benchmark IF-SitePred, a protein-ligand binding site prediction method which is based on the labelling of ESM-IF1 protein language model embeddings combined with point cloud annotation and clustering. We show that not only is IF-SitePred competitive with state-of-the-art methods when predicting binding sites on experimental structures, but it performs better on proxies for novel proteins where low accuracy has been simulated by molecular dynamics. Finally, IF-SitePred outperforms other methods if ensembles of predicted protein structures are generated.
- Open Access
Allosteric regulation and crystallographic fragment screening of SARS-CoV-2 NSP15 endoribonuclease
SARS-CoV-2 is the causative agent of COVID-19. The highly conserved viral NSP15 endoribonuclease, NendoU, is a key enzyme involved in viral immune evasion, and a promising target for the development of new classes of antivirals. Yet, the broad variety of recognition sequences, complex assembly and kinetics, and lack of structural complexes hampers the development of new competitive or allosteric inhibitors for this target. Here, we performed enzymatic characterization of NendoU in its monomeric and hexameric form, showing that hexamers are allosteric enzymes with a positive cooperative index of 2. By using cryo-EM at distinct pH’s combined with X-ray crystallography and structural analysis, we demonstrate the potential for NendoU to shift between open and closed states, and assembly in larger supramolecular entities, which might serve as a mechanism of self-regulation. Further, we report results from a large fragment screening campaign against NendoU, revealing multiple new allosteric sites for the development of inhibitors.
Open AccessAllosteric regulation and crystallographic fragment screening of SARS-CoV-2 NSP15 endoribonuclease
SARS-CoV-2 is the causative agent of COVID-19. The highly conserved viral NSP15 endoribonuclease, NendoU, is a key enzyme involved in viral immune evasion, and a promising target for the development of new classes of antivirals. Yet, the broad variety of recognition sequences, complex assembly and kinetics, and lack of structural complexes hampers the development of new competitive or allosteric inhibitors for this target. Here, we performed enzymatic characterization of NendoU in its monomeric and hexameric form, showing that hexamers are allosteric enzymes with a positive cooperative index of 2. By using cryo-EM at distinct pH’s combined with X-ray crystallography and structural analysis, we demonstrate the potential for NendoU to shift between open and closed states, and assembly in larger supramolecular entities, which might serve as a mechanism of self-regulation. Further, we report results from a large fragment screening campaign against NendoU, revealing multiple new allosteric sites for the development of inhibitors.
- Open Access
- 12 April 2022
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 14 (1) , 1-13
Galaxy workflows for fragment-based virtual screening: a case study on the SARS-CoV-2 main protease
We present several workflows for protein-ligand docking and free energy calculation for use in the workflow management system Galaxy. The workflows are composed of several widely used open-source tools, including rDock and GROMACS, and can be executed on public infrastructure using either Galaxy’s graphical interface or the command line. We demonstrate the utility of the workflows by running a high-throughput virtual screening of around 50000 compounds against the SARS-CoV-2 main protease, a system which has been the subject of intense study in the last year.
- 12 April 2022
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 14 (1) , 1-13
Open AccessGalaxy workflows for fragment-based virtual screening: a case study on the SARS-CoV-2 main protease
We present several workflows for protein-ligand docking and free energy calculation for use in the workflow management system Galaxy. The workflows are composed of several widely used open-source tools, including rDock and GROMACS, and can be executed on public infrastructure using either Galaxy’s graphical interface or the command line. We demonstrate the utility of the workflows by running a high-throughput virtual screening of around 50000 compounds against the SARS-CoV-2 main protease, a system which has been the subject of intense study in the last year.
- Open Access
Fragment libraries designed to be functionally diverse recover protein binding information more efficiently than standard structurally diverse libraries
Current fragment-based drug design relies on the efficient exploration of chemical space though the use of structurally diverse libraries of small fragments. However, structurally dissimilar compounds can exploit the same interactions on a target, and thus be functionally similar. Using 3D structures of many fragments bound to multiple targets, we examined if there exists a better strategy for selecting fragments for screening libraries. We show that structurally diverse fragments can be described as functionally redundant, often making the same interactions. Ranking fragments by the number of novel interactions they made, we show that functionally diverse selections of fragments substantially increase the amount of information recovered for unseen targets compared to other methods of selection. Using these results, we design small functionally efficient libraries that are able to give significantly more information about new protein targets than similarly sized structurally diverse libraries. By covering more functional space (rather than chemical space), more diverse sets of drug leads can be generated, increasing the chances of fragment screens resulting in viable drug candidates.
Open AccessFragment libraries designed to be functionally diverse recover protein binding information more efficiently than standard structurally diverse libraries
Current fragment-based drug design relies on the efficient exploration of chemical space though the use of structurally diverse libraries of small fragments. However, structurally dissimilar compounds can exploit the same interactions on a target, and thus be functionally similar. Using 3D structures of many fragments bound to multiple targets, we examined if there exists a better strategy for selecting fragments for screening libraries. We show that structurally diverse fragments can be described as functionally redundant, often making the same interactions. Ranking fragments by the number of novel interactions they made, we show that functionally diverse selections of fragments substantially increase the amount of information recovered for unseen targets compared to other methods of selection. Using these results, we design small functionally efficient libraries that are able to give significantly more information about new protein targets than similarly sized structurally diverse libraries. By covering more functional space (rather than chemical space), more diverse sets of drug leads can be generated, increasing the chances of fragment screens resulting in viable drug candidates.
- Open Access
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
There is currently a lack of effective drugs to treat people infected with SARS-CoV-2, the cause of the global COVID-19 pandemic. The SARS-CoV-2 Non-structural protein 13 (NSP13) has been identified as a target for anti-virals due to its high sequence conservation and essential role in viral replication. Structural analysis reveals two “druggable” pockets on NSP13 that are among the most conserved sites in the entire SARS-CoV-2 proteome. Here we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and a non-hydrolysable ATP analog. Comparisons of these structures reveal details of conformational changes that provide insights into the helicase mechanism and possible modes of inhibition. To identify starting points for drug development we have performed a crystallographic fragment screen against NSP13. The screen reveals 65 fragment hits across 52 datasets opening the way to structure guided development of novel antiviral agents.
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Open AccessStructure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
There is currently a lack of effective drugs to treat people infected with SARS-CoV-2, the cause of the global COVID-19 pandemic. The SARS-CoV-2 Non-structural protein 13 (NSP13) has been identified as a target for anti-virals due to its high sequence conservation and essential role in viral replication. Structural analysis reveals two “druggable” pockets on NSP13 that are among the most conserved sites in the entire SARS-CoV-2 proteome. Here we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and a non-hydrolysable ATP analog. Comparisons of these structures reveal details of conformational changes that provide insights into the helicase mechanism and possible modes of inhibition. To identify starting points for drug development we have performed a crystallographic fragment screen against NSP13. The screen reveals 65 fragment hits across 52 datasets opening the way to structure guided development of novel antiviral agents.
- Open Access
- 16 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (16) , eabf8711
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking
Massive fragment screening effort provides a foundation for the development of macrodomain inhibitors as novel antiviral agents.
- 16 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (16) , eabf8711
Open AccessFragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking
Massive fragment screening effort provides a foundation for the development of macrodomain inhibitors as novel antiviral agents.
- Open Access
Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
The global COVID-19 pandemic is caused by the SARS-CoV-2 virus and has infected over 100 million and caused over 2 million fatalities worldwide at the point of writing. There is currently a lack of effective drugs to treat people infected with SARS-CoV-2. The SARS-CoV-2 Non-structural protein 13 (NSP13) is a superfamily1B helicase that has been identified as a possible target for anti-viral drugs due to its high sequence conservation and essential role in viral replication. In this study we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and the non-hydrolysable ATP analogue (AMP-PNP). Comparisons of these structures reveal details of global and local conformational changes that are induced by nucleotide binding and hydrolysis and provide insights into the helicase mechanism and possible modes of inhibition. Structural analysis reveals two pockets on NSP13 that are classified as “druggable” and include one of the most conserved sites in the entire SARS-CoV-2 proteome. To identify possible starting points for anti-viral drug development we have performed a crystallographic fragment screen against SARS-CoV-2 NSP13 helicase. The fragment screen reveals 65 fragment hits across 52 datasets, with hot spots in pockets predicted to be of functional importance, including the druggable nucleotide and nucleic acid binding sites, opening the way to structure guided development of novel antiviral agents.
Open AccessStructure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
The global COVID-19 pandemic is caused by the SARS-CoV-2 virus and has infected over 100 million and caused over 2 million fatalities worldwide at the point of writing. There is currently a lack of effective drugs to treat people infected with SARS-CoV-2. The SARS-CoV-2 Non-structural protein 13 (NSP13) is a superfamily1B helicase that has been identified as a possible target for anti-viral drugs due to its high sequence conservation and essential role in viral replication. In this study we present crystal structures of SARS-CoV-2 NSP13 solved in the APO form and in the presence of both phosphate and the non-hydrolysable ATP analogue (AMP-PNP). Comparisons of these structures reveal details of global and local conformational changes that are induced by nucleotide binding and hydrolysis and provide insights into the helicase mechanism and possible modes of inhibition. Structural analysis reveals two pockets on NSP13 that are classified as “druggable” and include one of the most conserved sites in the entire SARS-CoV-2 proteome. To identify possible starting points for anti-viral drug development we have performed a crystallographic fragment screen against SARS-CoV-2 NSP13 helicase. The fragment screen reveals 65 fragment hits across 52 datasets, with hot spots in pockets predicted to be of functional importance, including the druggable nucleotide and nucleic acid binding sites, opening the way to structure guided development of novel antiviral agents.
- Open Access
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking
The SARS-CoV-2 macrodomain (Mac1) within the non-structural protein 3 (Nsp3) counteracts host-mediated antiviral ADP-ribosylation signalling. This enzyme is a promising antiviral target because catalytic mutations render viruses non-pathogenic. Here, we report a massive crystallographic screening and computational docking effort, identifying new chemical matter primarily targeting the active site of the macrodomain. Crystallographic screening of diverse fragment libraries resulted in 214 unique macrodomain-binding fragments, out of 2,683 screened. An additional 60 molecules were selected from docking over 20 million fragments, of which 20 were crystallographically confirmed. X-ray data collection to ultra-high resolution and at physiological temperature enabled assessment of the conformational heterogeneity around the active site. Several crystallographic and docking fragment hits were validated for solution binding using three biophysical techniques (DSF, HTRF, ITC). Overall, the 234 fragment structures presented explore a wide range of chemotypes and provide starting points for development of potent SARS-CoV-2 macrodomain inhibitors.
Open AccessFragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking
The SARS-CoV-2 macrodomain (Mac1) within the non-structural protein 3 (Nsp3) counteracts host-mediated antiviral ADP-ribosylation signalling. This enzyme is a promising antiviral target because catalytic mutations render viruses non-pathogenic. Here, we report a massive crystallographic screening and computational docking effort, identifying new chemical matter primarily targeting the active site of the macrodomain. Crystallographic screening of diverse fragment libraries resulted in 214 unique macrodomain-binding fragments, out of 2,683 screened. An additional 60 molecules were selected from docking over 20 million fragments, of which 20 were crystallographically confirmed. X-ray data collection to ultra-high resolution and at physiological temperature enabled assessment of the conformational heterogeneity around the active site. Several crystallographic and docking fragment hits were validated for solution binding using three biophysical techniques (DSF, HTRF, ITC). Overall, the 234 fragment structures presented explore a wide range of chemotypes and provide starting points for development of potent SARS-CoV-2 macrodomain inhibitors.